<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68923">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047240</url>
  </required_header>
  <id_info>
    <org_study_id>FILT01</org_study_id>
    <nct_id>NCT02047240</nct_id>
  </id_info>
  <brief_title>Renal Function Determination in Patients With Liver Cirrhosis</brief_title>
  <official_title>Renal Function Determination With Creatinine and Cystatin C Dependent Formulas Compared to Gold Standard DTPA-TC-99 (Diethylene-triamine-pentaacetate- Technetium-99) in Mexican Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <authority>Mexico: Secretaria de Salud</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have several ways to appropriately determine renal function in healthy patients and in
      several diseases, in cirrhotic population we dont have a precise tool that has sufficient
      precision that reflects glomerular function, although it has been reported that cystatin C,
      because of its nature could improve diagnostic accuracy to determinate the renal function in
      this population.

      The investigators hypothesize that glomerular filtration obtained from cystatin-C-derived
      formulas are more accurate when compared to creatinine-derived formulas with DTPA-Tc99
      (diethylene-triamine-pentaacetate- technetium-99) as gold standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to determine if the formulas for glomerular filtration are close to
      the estimation of actual renal function in mexican cirrhotic patients of different
      etiologies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Levels of glomerular filtration through several formulas in cirrhotic patients</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of glomerular filtration through several formulas dependent of creatinine and cystatin C and the gold standard</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Cirrhosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patients will be selected from the Liver Clinic from the Gastroenterology Department
        at a tertiary care center in Mexico
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis

          -  Stability in creatinine levels in the previous three months (variation &lt;0.3 mg/dL)

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Hepatocellular carcinoma

          -  Cerebrovascular events

          -  Decompensated heart failure

          -  Drugs that modify serum creatinine levels

          -  Renal replacement therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre, MD MSci</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldo Torre, MD MSci</last_name>
    <phone>54870900</phone>
    <phone_ext>2711</phone_ext>
    <email>detoal@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Aguirre-Valadez, MD</last_name>
    <phone>54870900</phone>
    <phone_ext>2711</phone_ext>
    <email>yanomani@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición &quot;Salvador Zubirán&quot;</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Torre, MD MSci</last_name>
      <phone>54870900</phone>
      <phone_ext>2711</phone_ext>
      <email>detoal@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Aguirre-Valadez, MD</last_name>
      <phone>54870900</phone>
      <phone_ext>2711</phone_ext>
      <email>yanomani@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Aguirre-Valadez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Niño-Cruz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aldo Torre, MD MSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>glomerular filtration</keyword>
  <keyword>cystatin C</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
